Introduction and Objective: Continuous Glucose Monitoring (CGM) is a powerful tool for managing type 2 diabetes (T2D). To maximize benefits on glycemic outcomes and diabetes self-management, clinicians should review CGM data to inform the plan of care. Here we describe a novel quality improvement (QI) metric assessing clinician review of CGM data for persons with T2D (PwT2D). Methods: The Michigan Collaborative for Type 2 Diabetes (MCT2D) aims to improve statewide T2D care. Using MCT2D registry data, we developed a QI metric measuring the proportion of CGM users with T2D managed by endocrinology who had CGM data reviewed at least once during the measurement year (01/01/2024-12/31/2024). CGM use was defined by ≥1 device billing code during the year, and review by Current Procedural Terminology (CPT) code 95251 billed within the 12 months plus a 2-month grace period. We then surveyed participating endocrinology practices to understand practice-level variability in CGM interpretation rates and opportunities for optimization. Results: Among the 3,344 PwT2D attributed to an MCT2D endocrinology practice on CGM, 2,924 (87.4%) had at least 1 CGM interpretation during the measurement year, with practice level performance ranging 18.1%-98.5%. The 50th, 75th, and 90th percentiles among endocrinology practices were 87.4%, 93.2%, and 95.9%. All 24 current endocrinology practices completed the corresponding survey conducted 7/2025-9/2025. Most, 22/24 (92%), agreed or strongly agreed that CGM interpretation is essential to high-quality T2D care. Nearly all practices, 23/24 (96%), had a process on place to download CGMs at in-person visits. Key barriers include challenges with the technical platform, forgotten login credentials, and receivers being unavailable. Conclusion: Endocrinology practices showed strong engagement in integrating CGM data into routine T2D care, though variability persists across sites. In the coming year, practices will use QI methods to implement targeted process improvements around CGM review. Disclosure J. Iyengar: None. L. Ang: None. K. Watson: None. J. Rau: None. J. Reiss: None. N. Bhomia: None. J.S. Weisensel: Stock/Shareholder; Current; Senseonics. H.L. Diez: None. L. Oshman: Stock/Shareholder; Current; Procter Ended; Viatris.
Iyengar et al. (Fri,) studied this question.